Valuation Contrasts

Intrinsic‑value models paint divergent views. A discounted‑cash‑flow (DCF) analysis estimates an intrinsic value of about $94 per share, implying a 43.4 % premium to the current price and signaling potential overvaluation in cash‑flow terms. In contrast, a fair‑value estimate of $163.47 based on long‑term automation and software themes places EMR at a discount to its average analyst price target. The company’s valuation checks score 4 of 6, reflecting a mixed picture: cash‑flow caution vs. strong order growth from accelerated digital automation and AI uptake in industrial markets.